|
Real-time
Euronext Paris
08:56:32 2026-11-18 EST
|
5-day change | 1st Jan Change | ||
| 0.4305 EUR | -0.81% |
|
-2.16% | +10.10% |
| 11-11 | Novacyt Secures Australian Regulatory Clearance for Yourgene Insight Diagnostic Assay | MT |
| 11-11 | Novacyt's Yourgene test authorized in Australia |
| Market Cap | 31.47M 34.66M 29.07M 26.22M 49.5M 3.24B 51.4M 350M 139M 1.75B 130M 127M 5.52B | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 33.42M 36.82M 30.87M 27.85M 52.58M 3.44B 54.59M 372M 147M 1.86B 138M 135M 5.86B | EV / Sales 2026 * |
1.09x | EV / Sales 2027 * | 1.04x |
| Free-Float |
99.83% | Yield 2026 * |
-
| Yield 2027 * | - |
Euronext ParisEUR
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| ALNOV | Real-time | |
| NCYT | Delayed | ||
| Real-time | |||
| NVYTF | Delayed | ||
| NYZ | Delayed | ||
| NYZ | Delayed | ||
| NYZ | Real-time | ||
| NYZ | Real-time | ||
| NCYT | Real-time | ||
| NCYT | Real-time |
Last Transcript: Novacyt
| 09-30 | Novacyt : Interim Accounts June 2026 (EN) | PU |
| 09-30 | Novacyt : Rapport DActivité Semestriel 2026 (EN) | PU |
| 04-30 | Novacyt : 2025 Management Report | PU |
| 04-30 | Novacyt : 2025 Group Consolidated Accounts | PU |
| 25-10-22 | Novacyt : NCYT Re-launch Investor Film | PU |
| 1 day | -0.81% | ||
| 1 week | -2.16% | ||
| Current month | -2.16% | ||
| 1 month | -6.82% | ||
| 3 months | -21.01% | ||
| 6 months | -17.37% | ||
| Current year | +10.10% |
| 1 week | 0.42 | 0.46 | |
| 1 month | 0.4 | 0.48 | |
| Current year | 0.29 | 1.04 | |
| 1 year | 0.29 | 1.04 | |
| 3 years | 0.29 | 1.59 | |
| 5 years | 0.29 | 5.89 | |
| 10 years | 0.06 | 13.96 |
| Manager | Title | Age | Since |
|---|---|---|---|
Lyn Rees
CEO | Chief Executive Officer | 53 | 2024-04-30 |
Steven Gibson
DFI | Director of Finance/CFO | 44 | 2019-12-31 |
Peter Coyne
COO | Chief Operating Officer | - | 2021-10-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 75 | 2006-07-02 | |
Juliet Thompson
BRD | Director/Board Member | 60 | 2017-06-26 |
Steven Gibson
BRD | Director/Board Member | 44 | 2024-01-01 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 3/30/26 | Buy | Chief Executive Officer | 1,792 | 0.0025% | ||
| 3/30/26 | Buy | Chairman | 15,228 | 0.0216% | ||
| 3/30/26 | Buy | Chairman | 56,732 | 0.0803% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.81% | -2.16% | -1.03% | -27.16% | 34.66M | ||
| +1.15% | -2.81% | +55.79% | +71.12% | 66.37B | ||
| +1.54% | -0.85% | +10.07% | +92.59% | 58.86B | ||
| +0.90% | +0.93% | +26.57% | +87.51% | 55.22B | ||
| +0.48% | -2.53% | +9.73% | +121.14% | 47.21B | ||
| -2.69% | -6.38% | +19.19% | +25.79% | 42.45B | ||
| -0.70% | +4.93% | +17.77% | +45.03% | 36.44B | ||
| -2.50% | -15.73% | +135.31% | +662.73% | 35.19B | ||
| +0.51% | -0.93% | +84.13% | +58.92% | 32.66B | ||
| -0.83% | +1.98% | -38.27% | +390.98% | 26.73B | ||
| Average | -0.28% | -1.94% | +31.93% | +152.86% | 40B | |
| Weighted average by Cap. | +0.03% | -2.18% | +35.32% | +147.45% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 30.52M 33.63M 28.2M 25.44M 48.02M 3.14B 49.86M 340M 134M 1.7B 126M 124M 5.36B | 34.86M 38.4M 32.2M 29.05M 54.85M 3.59B 56.95M 388M 153M 1.94B 144M 141M 6.12B |
| Net income | - | - |
| Net Debt | 1.96M 2.15M 1.81M 1.63M 3.08M 201M 3.2M 21.77M 8.61M 109M 8.08M 7.91M 343M | 4.84M 5.33M 4.47M 4.04M 7.62M 498M 7.91M 53.9M 21.32M 269M 20.01M 19.59M 850M |
Employees
228
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-11-18 | €0.4305 | -0.81% | 33,015 |
| 26-11-17 | €0.4340 | -3.56% | 9,057 |
| 26-11-16 | €0.4500 | 0.00% | 464,457 |
| 26-11-13 | €0.4500 | +4.65% | 156,799 |
| 26-11-12 | €0.4300 | -2.27% | 355,506 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- ALNOV Stock
Select your edition
All financial news and data tailored to specific country editions
















